CatalYm
Seedtable Score
56
Startups
3
Funding Rounds
8
Investors
$260.6m
Money raised
Overview
CatalYm shows strong potential with its focus on innovative immunotherapies for cancer patients. Based in Munich, it operates on a B2B model, supplying treatments to healthcare businesses. Backing from investors like Forbion Capital and Novartis Venture Fund indicates confidence in CatalYm's scientific approach and market potential. Unlike traditional cancer treatments like chemotherapy and radiation, which often have significant drawbacks, CatalYm aims to offer more effective, targeted solutions. By concentrating on pioneering immunotherapy approaches, the company is well-positioned to improve patient outcomes and set new standards in cancer care.
- Website: https://catalym.com
- Business model: b2b
- Company size: 11 - 51 employees
- Headquarters: Munich, Germany
- Founded: 2016
- Social accounts: Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (8)
Funding
Funding series
Funding Series Analysis
The company CatalYm has raised a total of $260.6m in funding over 3 rounds.
Key Insights:
- Series B: $59.05m
- Unknown: $51.55m
- Series D: $150m
CatalYm Series B (2020, $59M)
$59.05m
CatalYm Unknown (2022, $51M)
$51.55m
CatalYm Series D (2024, $150M)
$150m